Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 19/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 19/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011247 | 0.90 | CHRM2 (0.81) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL5011244 | 0.90 | CHRM2 (0.81) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL5006987 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL5006993 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL5007104 | 0.84 | CHRM2 (0.80) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL1924793 | 0.84 | CHRM2 (0.80) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL19856816 | 0.81 | CHRM3 (0.68) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL5006854 | 0.81 | CHRM2 (0.79) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5006852 | 0.81 | CHRM2 (0.79) | CHRM2CHRM1CHRM3 | |
| SCHEMBL5011147 | 0.80 | CHRM3 (0.67) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.